Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.
作者信息
Zhang David, Adegunsoye Ayodeji, Oldham Justin M, Wolters Paul J, Garcia Christine Kim, Newton Chad A
机构信息
Division of Pulmonary and Critical Care Medicine, Columbia University, New York, NY, USA.
Section of Pulmonary and Critical Care, University of Chicago, Chicago, IL, USA.
出版信息
Eur Respir J. 2024 Jan 18;63(1). doi: 10.1183/13993003.02146-2023. Print 2024 Jan.
Abstract
摘要
相似文献
1
Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.回复：非特发性肺纤维化间质性肺疾病中的端粒长度与免疫抑制
Eur Respir J. 2024 Jan 18;63(1). doi: 10.1183/13993003.02146-2023. Print 2024 Jan.
2
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.非特发性肺纤维化间质性肺疾病中的端粒长度与免疫抑制
Eur Respir J. 2024 Jan 18;63(1). doi: 10.1183/13993003.01806-2023. Print 2024 Jan.
3
Leukocyte telomere length: the dawn of a new era of personalised medicine in fibrotic interstitial lung diseases?白细胞端粒长度：纤维化间质性肺疾病个性化医疗新时代的曙光？
Eur Respir J. 2023 Nov 29;62(5). doi: 10.1183/13993003.01852-2023. Print 2023 Nov.
4
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.非特发性肺纤维化间质性肺疾病中的端粒长度与免疫抑制。
Eur Respir J. 2023 Nov 29;62(5). doi: 10.1183/13993003.00441-2023. Print 2023 Nov.
5
Peripheral and pulmonary telomere lengths in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases.非特发性肺纤维化间质性肺疾病患者的外周血和肺组织端粒长度
BMC Pulm Med. 2025 Aug 1;25(1):368. doi: 10.1186/s12890-025-03865-w.
6
Clinical Impact of Telomere Length Testing for Interstitial Lung Disease.端粒长度检测对间质性肺疾病的临床影响。
Chest. 2024 Nov;166(5):1071-1081. doi: 10.1016/j.chest.2024.06.006. Epub 2024 Jun 29.
7
Pulmonary fibrosis in the era of stratified medicine.分层医学时代的肺纤维化
Thorax. 2016 Dec;71(12):1154-1160. doi: 10.1136/thoraxjnl-2016-209172. Epub 2016 Oct 31.
8
Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.将基因组学纳入特发性肺纤维化的管理中。
Chest. 2019 May;155(5):1026-1040. doi: 10.1016/j.chest.2018.12.011. Epub 2019 Jan 17.
9
Impact of genetic factors on fibrosing interstitial lung diseases. Incidence and clinical presentation in adults.遗传因素对纤维化间质性肺疾病的影响。成人中的发病率及临床表现。
Presse Med. 2020 Jun;49(2):104024. doi: 10.1016/j.lpm.2020.104024. Epub 2020 May 11.
10
Significance of bronchiolocentric fibrosis in patients with histopathological usual interstitial pneumonia.特发性间质性肺炎患者中细支气管中心性纤维化的意义。
Histopathology. 2019 Jun;74(7):1088-1097. doi: 10.1111/his.13840. Epub 2019 Apr 25.
本文引用的文献
1
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.非特发性肺纤维化间质性肺疾病中的端粒长度与免疫抑制。
Eur Respir J. 2023 Nov 29;62(5). doi: 10.1183/13993003.00441-2023. Print 2023 Nov.
2
Telomere length associates with chronological age and mortality across racially diverse pulmonary fibrosis cohorts.端粒长度与种族多样化的肺纤维化队列中的年龄和死亡率相关。
Nat Commun. 2023 Mar 17;14(1):1489. doi: 10.1038/s41467-023-37193-6.
3
Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosis.全基因组测序在评估肺纤维化风险和临床相关结局中的效用。
Eur Respir J. 2022 Dec 22;60(6). doi: 10.1183/13993003.00577-2022. Print 2022 Dec.
4
Lung function trajectory in progressive fibrosing interstitial lung disease.进行性肺纤维化性间质性肺疾病中的肺功能轨迹。
Eur Respir J. 2022 Jun 16;59(6). doi: 10.1183/13993003.01396-2021. Print 2022 Jun.
5
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.吡非尼酮治疗非特发性肺纤维化的进展性肺纤维化间质性肺疾病患者（RELIEF）：一项双盲、随机、安慰剂对照、2b 期试验。
Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30.
6
The burden of progressive fibrotic interstitial lung disease across the UK.英国进行性纤维性间质性肺疾病的负担。
Eur Respir J. 2021 Jul 8;58(1). doi: 10.1183/13993003.00221-2021. Print 2021 Jul.
7
Psychological impact of genetic and clinical screening for pulmonary fibrosis on asymptomatic first-degree relatives of affected individuals.遗传性和临床性肺纤维化筛查对无症状肺纤维化患者一级亲属的心理影响。
Thorax. 2021 Jun;76(6):621-623. doi: 10.1136/thoraxjnl-2020-216244. Epub 2021 Jan 22.
8
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.尼达尼布治疗进行性纤维化间质性肺疾病。
N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.
9
Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.特发性肺纤维化中端粒长度与免疫抑制药物的使用。
Am J Respir Crit Care Med. 2019 Aug 1;200(3):336-347. doi: 10.1164/rccm.201809-1646OC.
10
Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive.端粒相关的肺纤维化在诊断上具有异质性，但均呈进行性发展。
Eur Respir J. 2016 Dec;48(6):1710-1720. doi: 10.1183/13993003.00308-2016. Epub 2016 Aug 18.
Zotero 插件